HC Wainwright reissued their buy rating on shares of Lipocine (NASDAQ:LPCN) in a report published on Monday morning, The Fly reports. HC Wainwright currently has a $3.00 target price on the specialty pharmaceutical company’s stock.
Several other research analysts also recently commented on the stock. LADENBURG THALM/SH SH reissued a buy rating on shares of Lipocine in a report on Thursday, January 17th. ValuEngine raised shares of Lipocine from a sell rating to a hold rating in a report on Wednesday, January 2nd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of Buy and an average price target of $4.83.
Shares of NASDAQ:LPCN opened at $2.19 on Monday. The company has a quick ratio of 4.63, a current ratio of 4.63 and a debt-to-equity ratio of 0.73. Lipocine has a one year low of $1.03 and a one year high of $2.64. The firm has a market capitalization of $49.31 million, a price-to-earnings ratio of -3.98 and a beta of 0.68.
A number of large investors have recently made changes to their positions in LPCN. JPMorgan Chase & Co. lifted its holdings in shares of Lipocine by 145.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 95,429 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 56,606 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock worth $1,032,000 after acquiring an additional 35,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock worth $1,032,000 after acquiring an additional 35,000 shares during the last quarter. 9.82% of the stock is owned by hedge funds and other institutional investors.
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.